Technologies

EMMPRIN

  • Category: Pharma
  • Investment Status: Advanced
  • Medical Field: Oncology
  • Medical Center: Carmel Medical Center and Technion
  • Inventors: Prof Haim Bitterman, Prof Nitza Lahat, Dr Michal Rahat

Background: Extracellular matrix metalloproteinase inducer (EMMPRIN or CD147 or basigin) is a protumoral protein expressed by both tumor and stroma cells that has been shown to induce both the pro-angiogenic vascular endothelial growth factor (VEGF) and the extracellular matrix (ECM) degrading matrix metalloproteinases (MMPs), including MMP-9. In addition, EMMPRIN is involved in tumor metabolism, in tumor drug resistance and in leukocyte chemotaxis.

Technology: EMMPRIN, with its multiple functions in tumor survival and growth, may serve as an attractive target in cancer therapy, as well as in chronic inflammatory diseases, so that immunizing against this one molecule may simultaneously affect many of its functions.